1. Katelin Thomas, MPH, MCHES Sofia Porres, MA Cristina Witzke, MPH
Stony Brook Medicine
Katelin Thomas, MPH, MCHES
Sofia Porres, MA
Cristina Witzke, MPH

2. SBM We reviewed our 2016 patient list
37 patients with no visit in 2016
11 patients transferred, 5 patients are deceased
2.9% (n=21) have not been seen yet in 2016 (as of September 16)
Gender and Viral Load
Males (n=9)
Female (n=12)
7 = undetectable
7 = undetectable
2 = <500
1 = <10,000
1 = 12,000
4 = > 20,000

3. SBM 2.9% (n=21) have not been seen yet in 2016 (as of September 16)
33.33% of patients have an upcoming appointment (n=16)
9.52% of patients need an appointment (n=2)
57.14% of patients are lost to follow-up (n=12)
Males (n=4)
Female (n=12)
4 = VL undetectable
2 = VL undetectable
1 = VL in 200s
1 = VL <100,000
Males (n=1)
Female (n=1)
1 = VL undetectable
2 = VL undetectable

4. SBM Patients lost to follow-up (n=12)
Last seen 2013: n= 2, viral load undetectable
Last seen 2014: n= 3
1 patient was only seen once, went to drug rehab, then lost to follow-up (no contact information)
1 patient was incarcerated, released in 2015, then lost to follow-up (no contact information)
Last seen 2015: n=7
Males (n=4)
Female (n=8)
2 = VL undetectable
2 = VL undetectable
1 = VL < 500
1 = <10,000
1 = VL 12,000
3 = VL > 20,000
Males (n=2)
Female (n=5)
2 = VL undetectable
3 = VL undetectable
2 = >50,000

5. SBM
For our patients not seen since 2013, 2014 how can we find out if they are being seen somewhere else?
Can we contact the DOH to see if these patients are in care elsewhere?
Why are more females vs males lost to follow-up and detectable?
What can we do to improve engagement and adherence?